Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Study to Evaluate the Safety, Tolerability, PK/PD Profile, and Efficacy of Multiple Doses of BGM0504 Injection in Overweight or Obese Subjects Without Diabetes

NCT06973681 is registered in ClinicalTrials.gov with BrightGene Bio-Medical Technology Co., Ltd. as lead sponsor.

NCT NCT06973681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06973681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Study to Evaluate the Safety, Tolerability, PK/PD Profile, and Efficacy of Multiple Doses of BGM0504 Injection in Overweight or Obese Subjects Without Diabetes
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
October 13, 2023
Completion date
September 13, 2024
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overweight or obesity